Startups roll out AI-powered burnout buster for physicians

Two established AI startups are partnering to supply a digital toolkit for physicians at risk of burnout. The companies’ aim is to offer these doctors various prevention and treatment resources any place, any time. 

The agreement will combine Rx.Health’s EHR-based “digital therapeutics” prescribing system—which till now has been used by physicians treating patients with wearables, mobile apps and remote monitoring—with Suki’s AI-powered voice assistant for physicians.

Users will receive individualized educational materials, tips and digital aids to encourage self-care, along with helps for streamlining documentation chores and easing other administrative burdens associated with physician burnout.

According to a joint announcement, the Suki component is the first of several offerings planned as part of the new physician-focused toolkit.

“Since the reasons for burnout are multifactorial, we felt a comprehensive toolkit approach that combines best-of-class digital therapeutics and AI solutions under one umbrella will be the best enterprise-wide approach,” said Ashish Atreja, chief innovation officer in medicine at Mount Sinai Health System in New York, from which RxHealth spun off in 2016.

Atreja also serves Rx.Health as chief strategy officer.

Suki was founded in 2016 by Punit Soni, a former executive at Google and Flipkart.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.